BeOne Medicines (ONC) Retained Earnings (2015 - 2026)

BeOne Medicines (ONC) has reported Retained Earnings for 12 consecutive years, with $12.9 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings rose 5.38% year-over-year to $12.9 billion; the TTM figure through Mar 2026 stood at $12.9 billion (up 5.38% YoY), while the FY2025 annual figure was -$8.3 billion, down 168.83% from the prior year.
• Retained Earnings advanced to $12.9 billion in Q1 2026 per ONC's latest filing, from -$8.3 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $12.9 billion in Q1 2026 and bottomed at -$8.5 billion in Q2 2025.
• Historically, Retained Earnings has averaged $6.4 billion across 5 years, with a median of $11.5 billion in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 781.69% — and 2023, when it soared 14353.51%.
• BeOne Medicines' Retained Earnings stood at $11.5 billion in 2022, then climbed by 0.5% to $11.6 billion in 2023, then gained by 4.22% to $12.1 billion in 2024, then tumbled by 168.83% to -$8.3 billion in 2025, then soared by 255.13% to $12.9 billion in 2026.
• Business Quant data shows ONC's Retained Earnings at $12.9 billion in Q1 2026, -$8.3 billion in Q4 2025, and $12.6 billion in Q3 2025.